Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>
<a href="https://smartkarma.com/entities/aim-vaccine-co-ltd">AIM Vaccine</a> is a leading, fully-integrated vaccine company in China, holding significant market shares in Hepatitis B and Rabies vaccines, but has faced considerable financial headwinds with persistent net losses and revenue pressure in recent years.</li>
  <li>The company is at a potential inflection point, with a robust pipeline of over 20 vaccine candidates, including several late-stage assets like a 13-valent pneumococcal conjugate vaccine (PCV13) and a serum-free rabies vaccine, which could drive future growth and a return to profitability.</li>
  <li>Strategic focus on high-potential mRNA technology, with RSV and shingles vaccine candidates receiving clinical trial approvals in both the U.S. and China, positions AIM to compete in the next generation of vaccine innovation, though significant clinical and commercial risks remain.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
AIM Vaccine is a leading, fully-integrated vaccine company in China, holding significant market shares in Hepatitis B and Rabies vaccines, but has faced considerable financial headwinds with persistent net losses and revenue pressure in recent years.
  The company is at a potential inflection point, with a robust pipeline of over 20 vaccine candidates, including several late-stage assets like a 13-valent pneumococcal conjugate vaccine (PCV13) and a serum-free rabies vaccine, which could drive future growth and a return to profitability.
  Strategic focus on high-potential mRNA technology, with RSV and shingles vaccine candidates receiving clinical trial approvals in both the U.S. and China, positions AIM to compete in the next generation of vaccine innovation, though significant clinical and commercial risks remain.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

China

AIM Vaccine Co., Ltd. manufactures and distributes vaccines. The Company produces recombinant hepatitis b vaccines, freeze dried human rabies vaccines, inactivated hepatitis a vaccines, live attenuated parotitis vaccines, and others. AIM Vaccine also operates import and export businesses.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

AIM Vaccine (6660 HK)

Primer: AIM Vaccine (6660 HK) - Aug 2026

AIM Vaccine is a leading, fully-integrated vaccine company in China, holding significant market shares in Hepatitis B and Rabies vaccines, but...

αSK Primers

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)